Full details about methyldopa drug 1. Introduction 2. General objective 3. Specific objectives 4. Index of drugs 5. Introduction 6. Pharmecodaynemic and pharmacokinetics 7. Classification, factors affecting action of drugs , Trade and pharmaceutical name 8. Preparation, strength and dose 9. Mechanism of action 10. Indications and contraindications 11. Action , adverse effects ,drug interactions 12. Nursing responsibility 13. Conclusion 14. Bibliography
Reading Document
Medical Text Search
methyldopa pharmacodynamics pharmacokinetics mechanism of action
Medical Text Search
methyldopa indications contraindications adverse effects drug interactions nursing
GradeResponse
GradeResponse
The database returned minimal results; I will now build the comprehensive document fully from established pharmacological knowledge and the retrieved reference.
Methyldopa — Comprehensive Drug Study
1. INTRODUCTION
Antihypertensive pharmacotherapy has evolved considerably over the past seven decades, yet certain older agents remain clinically indispensable. Methyldopa (α-methyldopa) is one such agent — a centrally acting antihypertensive that was introduced in the 1960s and continues to occupy a prominent place in the management of hypertension, especially during pregnancy. It was among the first drugs shown to reduce blood pressure without causing reflex tachycardia by acting on central adrenergic pathways rather than the heart or peripheral vasculature directly.
Understanding methyldopa in depth is essential for healthcare professionals because it exemplifies an entirely different pharmacological strategy compared to diuretics, beta-blockers, or calcium-channel blockers. Its selective action on the central nervous system, its established safety profile in obstetrics, and its complex adverse-effect spectrum make it a valuable model drug for studying antihypertensive pharmacology.
2. GENERAL OBJECTIVE
To provide a thorough, evidence-based overview of methyldopa that enables healthcare students, nurses, and clinicians to understand, prescribe, administer, monitor, and counsel patients on this drug with confidence and competence.
3. SPECIFIC OBJECTIVES
By the end of this study, the reader will be able to:
- Define methyldopa and describe its historical development and therapeutic relevance.
- Explain the pharmacodynamic and pharmacokinetic profile of methyldopa.
- Classify methyldopa within the antihypertensive drug categories.
- List the trade names, pharmaceutical preparations, strengths, and dosing regimens.
- Describe the mechanism of action at the cellular and systems level.
- Enumerate the indications and contraindications for methyldopa therapy.
- Identify the therapeutic actions, adverse effects, and clinically significant drug interactions.
- Apply nursing responsibilities before, during, and after methyldopa administration.
- Summarize the key points in a clear conclusion.
4. INDEX OF DRUGS (Centrally Acting Antihypertensives — Class)
| Drug | Class | Primary Use |
|---|---|---|
| Methyldopa | Central α₂-agonist (prodrug) | Hypertension, gestational HTN |
| Clonidine | Central α₂-agonist | Hypertension, ADHD, pain |
| Guanfacine | Central α₂-agonist | Hypertension, ADHD |
| Guanabenz | Central α₂-agonist | Hypertension |
| Moxonidine | Central I₁ imidazoline agonist | Hypertension |
5. INTRODUCTION (Drug-Specific)
Methyldopa (chemical name: L-α-methyl-3,4-dihydroxyphenylalanine) is a phenylalanine derivative and structural analogue of the amino acid DOPA. It was developed by George Hitchings and colleagues and became commercially available in the early 1960s under the brand name Aldomet.
It is classified as a centrally acting antiadrenergic agent and functions as a prodrug — it must be metabolized in the central nervous system (CNS) to its active metabolite, alpha-methylnorepinephrine, to exert its antihypertensive effect. This metabolite stimulates central α₂-adrenergic receptors, leading to a reduction in sympathetic outflow to the heart and peripheral vessels, ultimately lowering blood pressure.
Methyldopa is listed on the World Health Organization (WHO) List of Essential Medicines and remains the first-line agent for hypertension in pregnancy according to numerous international guidelines, owing to its long safety record in obstetric practice.
6. PHARMACODYNAMICS AND PHARMACOKINETICS
6.1 Pharmacodynamics
Pharmacodynamics describes what the drug does to the body.
Primary Effect:
Methyldopa lowers arterial blood pressure predominantly through a central mechanism. After conversion to alpha-methylnorepinephrine in the brainstem, it stimulates presynaptic and postsynaptic α₂-adrenergic receptors in the nucleus tractus solitarius (NTS) and rostral ventrolateral medulla (RVLM), reducing sympathetic outflow.
Hemodynamic Effects:
| Parameter | Effect |
|---|---|
| Systolic blood pressure | Decreased |
| Diastolic blood pressure | Decreased |
| Heart rate | Slightly decreased or unchanged |
| Cardiac output | Maintained or slightly decreased |
| Peripheral vascular resistance | Decreased |
| Renal blood flow | Maintained |
| Plasma renin activity | Decreased |
- Does not cause significant reflex tachycardia (unlike direct vasodilators).
- Does not reduce renal blood flow significantly — useful in patients with renal impairment.
- Causes mild sodium and water retention (compensatory), often requiring concomitant diuretic use.
Positive Baroreceptor Response:
Unlike many vasodilators, methyldopa does not blunt the baroreceptor reflex, which helps explain why orthostatic hypotension, while possible, is less severe than with ganglionic blockers.
6.2 Pharmacokinetics
| Parameter | Details |
|---|---|
| Route of administration | Oral (tablets), Intravenous (IV injection) |
| Bioavailability | ~25–50% (oral); incomplete due to first-pass metabolism and incomplete absorption |
| Onset of action | Oral: 4–6 hours; IV: 4–6 hours (slower than expected for IV) |
| Peak effect | 6–8 hours after oral dose |
| Duration of action | 12–24 hours (single dose); 24–48 hours after stopping chronic therapy |
| Protein binding | Minimal (~15%) |
| Volume of distribution | 0.6 L/kg |
| Metabolism | Hepatic (conjugation to methyldopa-O-sulfate); CNS conversion to alpha-methylnorepinephrine (active), alpha-methyldopamine, and alpha-methylepinephrine |
| Half-life | ~1.7 hours (normal renal function) |
| Elimination | Renal — ~70% excreted unchanged or as sulfate conjugates in urine |
| Renal adjustment | Required in renal failure; accumulation risk |
| Placental transfer | Yes — crosses placenta; safe in pregnancy |
| Breast milk | Present in small amounts; generally considered compatible with breastfeeding |
| Blood-brain barrier | Crosses via aromatic amino acid transporter (LAT1) |
Special Consideration — Renal Impairment:
Because the majority of methyldopa and its metabolites are renally excreted, dose interval should be extended in patients with impaired renal function:
- CrCl 10–50 mL/min: dose every 8–12 hours
- CrCl <10 mL/min: dose every 12–24 hours
7. CLASSIFICATION, FACTORS AFFECTING DRUG ACTION, TRADE AND PHARMACEUTICAL NAMES
7.1 Classification
| Classification Basis | Category |
|---|---|
| Pharmacological class | Centrally acting antiadrenergic agent |
| Mechanism class | Central α₂-adrenergic agonist (via active metabolite) |
| Chemical class | Catecholamine precursor / phenylalanine analogue |
| Therapeutic class | Antihypertensive |
| Pregnancy category (FDA) | Category B |
| WHO essential medicine | Yes |
7.2 Factors Affecting Drug Action
Patient-Related Factors:
- Age: Elderly patients are more sensitive to hypotensive and sedative effects; start at lower doses.
- Renal function: Reduced clearance leads to drug accumulation — dose adjustment mandatory.
- Hepatic disease: Active hepatitis or cirrhosis is a contraindication; impaired metabolism alters drug levels.
- Pregnancy: Physiological changes in blood volume and renal clearance affect drug distribution.
- Genetic polymorphisms: Variations in aromatic L-amino acid decarboxylase may affect conversion to active metabolite.
Drug-Related Factors:
- Dose: Dose-dependent antihypertensive and sedative effects.
- Route: IV route bypasses first-pass effect but paradoxically has a slow onset (4–6 hours).
- Food interactions: High-protein meals may compete for intestinal amino acid transporters, reducing absorption.
- Salt and fluid intake: High sodium diets cause sodium retention, blunting antihypertensive efficacy.
- Concurrent diuretic use: Enhances antihypertensive effect.
- Iron supplements: Chelate methyldopa in the GI tract, significantly reducing absorption.
Environmental/External Factors:
- Stress and sympathetic activation can override central effects.
- Abrupt withdrawal after chronic use can cause rebound hypertension.
7.3 Trade and Pharmaceutical Names
| Name Type | Names |
|---|---|
| Generic (INN) name | Methyldopa |
| Chemical name | L-α-Methyl-3,4-dihydroxyphenylalanine |
| Trade names | Aldomet (most widely known), Aldoril (combination with hydrochlorothiazide), Dopamet, Medopa, Medomet, Hypernol, Presinol, Sembrina |
| Pharmaceutical name | Methyldopum (Latin pharmacopoeia) |
| CAS number | 555-30-6 |
| Molecular formula | C₁₀H₁₃NO₄ |
| Molecular weight | 211.21 g/mol |
8. PREPARATION, STRENGTH, AND DOSE
8.1 Available Preparations and Strengths
| Formulation | Strength |
|---|---|
| Oral tablets | 125 mg, 250 mg, 500 mg |
| Oral suspension | Extemporaneously compounded (not standard commercial) |
| IV injection (as Methyldopate HCl) | 250 mg/5 mL (50 mg/mL) vials |
Note: The parenteral form is methyldopate hydrochloride, the ethyl ester prodrug that is more water-soluble for IV use.
8.2 Dosing Regimens
Adults — Oral (Hypertension)
| Indication | Initial Dose | Maintenance Dose | Maximum Dose |
|---|---|---|---|
| Hypertension | 250 mg 2–3 times/day | 500–2000 mg/day in 2–4 divided doses | 3000 mg/day |
| Hypertensive urgency (IV) | 250–500 mg IV over 30–60 min | Repeat q6h PRN | 1000 mg per dose |
Pediatrics — Oral
| Weight | Initial Dose | Maximum Dose |
|---|---|---|
| Children | 10 mg/kg/day in 2–4 divided doses | 65 mg/kg/day or 3000 mg/day (whichever is lower) |
Pregnancy (Gestational Hypertension / Chronic HTN in Pregnancy)
| Dose | Notes |
|---|---|
| 250–500 mg orally 2–3 times/day | First-line agent; titrate to BP control |
| Maximum: 3000 mg/day | Monitor for maternal sedation and neonatal effects |
Administration Instructions:
- May be taken with or without food.
- Tablets should be swallowed whole.
- IV infusion should be diluted in 100 mL D5W and infused over 30–60 minutes.
- Do not abruptly discontinue — taper to avoid rebound hypertension.
9. MECHANISM OF ACTION
Methyldopa exerts its antihypertensive effect through a multi-step central mechanism:
Step-by-Step Mechanism
Step 1: ABSORPTION
Methyldopa is absorbed from the GI tract via aromatic amino acid transporters (shared with L-DOPA).
Step 2: CNS PENETRATION
Methyldopa crosses the blood-brain barrier using the same LAT1 transporter.
Step 3: CENTRAL DECARBOXYLATION
In adrenergic neurons of the brainstem (especially nucleus tractus solitarius),
methyldopa is decarboxylated by aromatic L-amino acid decarboxylase (DOPA decarboxylase)
→ forms ALPHA-METHYLDOPAMINE
Step 4: HYDROXYLATION (Beta-hydroxylation)
Alpha-methyldopamine is hydroxylated by dopamine β-hydroxylase
→ forms ALPHA-METHYLNOREPINEPHRINE (the ACTIVE metabolite)
Step 5: STORAGE & RELEASE
Alpha-methylnorepinephrine is stored in synaptic vesicles and released
in place of normal norepinephrine
Step 6: α₂-RECEPTOR STIMULATION
Alpha-methylnorepinephrine is a potent α₂-adrenergic receptor agonist.
It stimulates PRESYNAPTIC α₂ receptors in the brainstem cardiovascular centers
(nucleus tractus solitarius, RVLM), acting as a FALSE TRANSMITTER.
Step 7: REDUCED SYMPATHETIC OUTFLOW
α₂ stimulation → inhibits adenylyl cyclase → reduced cAMP →
decreased norepinephrine release → reduced sympathetic tone to
heart and peripheral vasculature
Step 8: HEMODYNAMIC RESULT
↓ Total peripheral resistance + mild ↓ cardiac output
→ DECREASED BLOOD PRESSURE
Summary Table
| Step | Process | Location |
|---|---|---|
| Prodrug absorption | GI → circulation → brain | Small intestine |
| Decarboxylation | Methyldopa → alpha-methyldopamine | Brainstem neurons |
| Beta-hydroxylation | Alpha-methyldopamine → alpha-methylnorepinephrine | Brainstem neurons |
| False transmitter release | Replaces norepinephrine in vesicles | Sympathetic nerve terminals |
| α₂-agonism | Reduces sympathetic outflow | NTS, RVLM, brainstem |
| BP reduction | ↓ SVR, ↓ HR, ↓ BP | Heart & peripheral vessels |
Key concept: Methyldopa is a false neurotransmitter — it does not block adrenergic receptors but replaces the endogenous transmitter with a weaker, α₂-selective agonist that reduces rather than stimulates sympathetic activity.
10. INDICATIONS AND CONTRAINDICATIONS
10.1 Indications
| Indication | Notes |
|---|---|
| Essential hypertension | Oral therapy; often combined with a diuretic |
| Hypertension in pregnancy (first-line) | Safest agent; established 40+ year track record |
| Gestational hypertension / Pre-eclampsia | Widely used internationally |
| Hypertensive urgency (IV) | When oral route unavailable |
| Hypertension with renal impairment | Preserves renal blood flow (with dose adjustment) |
| Hypertension in elderly | Effective, though sedation may be limiting |
| Renovascular hypertension | Useful adjunct |
10.2 Contraindications
| Contraindication | Reason |
|---|---|
| Active hepatic disease (acute hepatitis, cirrhosis) | Risk of hepatotoxicity; impaired metabolism |
| Previous methyldopa-associated liver disease | Risk of recurrence — absolute contraindication |
| Hemolytic anemia (previous drug-related) | Risk of severe immune hemolysis |
| Hypersensitivity to methyldopa | Allergic reactions |
| Pheochromocytoma | Paradoxical hypertension possible |
| Concurrent MAO inhibitor (MAOI) use | Risk of hypertensive crisis and CNS excitation |
| Depression (relative) | Methyldopa can worsen depressive symptoms |
| Renal failure (severe, uncorrected) | Drug accumulation (use with caution + dose adjust) |
11. ACTIONS, ADVERSE EFFECTS, AND DRUG INTERACTIONS
11.1 Therapeutic Actions
- Antihypertensive: Reduces both systolic and diastolic blood pressure.
- Reduces sympathetic tone: Lowers peripheral vascular resistance without significantly reducing cardiac output.
- Preserves renal perfusion: Unlike many antihypertensives, it does not compromise renal blood flow.
- Safe in pregnancy: Does not cause fetal/neonatal complications at therapeutic doses.
- Reduces plasma renin activity: Mild additional mechanism contributing to BP reduction.
11.2 Adverse Effects
CNS Effects (Most Common — due to central mechanism)
| Adverse Effect | Frequency | Notes |
|---|---|---|
| Sedation / Drowsiness | Very common | Especially at treatment initiation; often diminishes |
| Fatigue / Lethargy | Common | Dose-dependent |
| Depression | Common | Patients with history of depression at high risk |
| Nightmares / disturbed sleep | Occasional | |
| Cognitive impairment | Occasional | Especially in elderly |
| Headache | Common | |
| Parkinsonism-like symptoms | Rare | Tremor, bradykinesia |
Cardiovascular Effects
| Adverse Effect | Notes |
|---|---|
| Orthostatic (postural) hypotension | Especially on rising; risk of falls |
| Bradycardia | Mild; due to reduced sympathetic tone |
| Edema | Sodium and water retention — may require diuretic |
| Aggravation of angina | Rare |
Hematological Effects
| Adverse Effect | Notes |
|---|---|
| Positive Coombs test | 10–20% of patients on prolonged therapy; antibody production against RBCs |
| Hemolytic anemia | ~0.5–1% of patients with positive Coombs; potentially life-threatening |
| Thrombocytopenia | Rare |
| Leukopenia | Rare |
Hepatic Effects
| Adverse Effect | Notes |
|---|---|
| Elevated liver enzymes (AST, ALT) | Common; usually transient |
| Drug-induced hepatitis | Rare but serious; occurs within first 3 months |
| Hepatic necrosis | Rare; potentially fatal |
Endocrine/Other Effects
| Adverse Effect | Notes |
|---|---|
| Hyperprolactinemia | Via dopamine antagonism → galactorrhea, gynecomastia, impotence |
| Sexual dysfunction | Impotence in men, decreased libido |
| Dry mouth | Due to reduced salivary sympathetic tone |
| Nasal congestion | Due to vasodilation of nasal mucosa |
| Drug fever | Rare hypersensitivity reaction |
| Lupus-like syndrome | Rare; positive ANA titers |
| Skin reactions | Rash, urticaria (rare) |
11.3 Drug Interactions
| Interacting Drug/Class | Interaction | Clinical Management |
|---|---|---|
| MAO inhibitors (phenelzine, tranylcypromine) | Hypertensive crisis, CNS excitation — contraindicated | Avoid concurrent use; 14-day washout required |
| Iron salts (ferrous sulfate, ferrous gluconate) | Chelation of methyldopa in GI tract → reduced absorption by up to 79% | Separate administration by ≥2 hours |
| Antidepressants (TCAs) | Reduced antihypertensive effect | Monitor BP; may need dose adjustment |
| Sympathomimetics (ephedrine, pseudoephedrine) | Antagonize antihypertensive effect | Avoid; caution with OTC decongestants |
| Lithium | Methyldopa may increase lithium toxicity | Monitor lithium levels; watch for toxicity signs |
| Haloperidol | CNS toxicity (dementia, confusion reported) | Avoid combination |
| Levodopa | Competition for same aromatic amino acid transporter; variable — may increase or decrease effects of both | Monitor carefully |
| Beta-blockers | Additive hypotension; possible paradoxical HTN (rare) | Monitor BP |
| Anesthetics/General anesthesia | Enhanced hypotensive effect during surgery | Inform anesthesiologist; methyldopa may be continued or held per anesthesiologist discretion |
| Alcohol | Enhanced sedation and hypotension | Counsel patients to avoid alcohol |
| NSAIDs (ibuprofen, indomethacin) | Reduce antihypertensive efficacy via sodium retention and prostaglandin inhibition | Monitor BP; minimize NSAID use |
| Diuretics | Additive hypotension (often desirable); used in combination | Monitor for excessive hypotension and electrolytes |
| Other antihypertensives | Additive hypotensive effect | Titrate doses carefully |
12. NURSING RESPONSIBILITIES
12.1 Pre-Administration Assessment
| Assessment | Rationale |
|---|---|
| Obtain complete medication history | Identify interactions (especially MAOIs, iron, lithium) |
| Measure baseline blood pressure (both arms, lying and standing) | Establish baseline; detect pre-existing orthostatic hypotension |
| Check baseline heart rate | Bradycardia may be worsened |
| Review renal function tests (BUN, creatinine, eGFR) | Dose adjustment needed in renal impairment |
| Review liver function tests (AST, ALT, bilirubin) | Contraindicated in active liver disease |
| Obtain baseline CBC with differential | Detect pre-existing anemia or hematological disorders |
| Direct Coombs test baseline | Important reference point before therapy |
| Assess for depression, history of mental illness | CNS depression effects may worsen mood disorders |
| Pregnancy and lactation status | First-line in pregnancy; confirm suitability |
| Assess for signs of fluid retention (edema, weight) | Establish baseline |
| Assess patient's knowledge and ability to comply | Adherence education needed |
12.2 During Administration
| Responsibility | Rationale |
|---|---|
| Administer oral tablet with or without food consistently | Maintain consistent absorption patterns |
| For IV administration: dilute in 100 mL D5W, infuse over 30–60 min | Prevents rapid BP drop; reduces phlebitis risk |
| Do NOT infuse IV rapidly (bolus) | Risk of severe hypotension |
| Monitor BP every 30 minutes during IV infusion | Detect hypotension promptly |
| Implement fall prevention protocols | Orthostatic hypotension risk — especially in elderly |
| Separate administration from iron supplements by ≥2 hours | Prevents chelation and absorption failure |
| Monitor for sedation, especially in first 1–2 weeks | CNS depression is most common early adverse effect |
| Observe for signs of fluid retention (daily weight, edema) | May require diuretic addition |
12.3 Post-Administration / Ongoing Monitoring
| Parameter | Frequency | Action if Abnormal |
|---|---|---|
| Blood pressure (lying and standing) | With each dose adjustment; then periodically | Report symptomatic hypotension; adjust dose |
| Heart rate | Regularly | Report bradycardia <60 bpm |
| Liver function tests (AST, ALT, ALP, bilirubin) | Baseline, then at 6–12 weeks, then every 6 months | Discontinue if significant elevation or hepatitis signs |
| CBC with differential | Baseline, then every 6–12 months | Evaluate for hemolytic anemia; report unusual fatigue or jaundice |
| Direct Coombs test | Every 6–12 months on long-term therapy | Positive result: monitor for hemolysis; discontinue if hemolytic anemia confirmed |
| Renal function (BUN, creatinine) | Periodically | Adjust dose as needed |
| Mental status / mood | Each visit | Watch for depression; refer if indicated |
| Weight / edema | Daily (inpatient) or each visit | Significant gain >1 kg/day → report possible fluid retention |
| Urine color | Daily | Dark/cola-colored urine → possible hemolysis or hepatotoxicity — report immediately |
12.4 Patient and Family Education
| Topic | Key Teaching Points |
|---|---|
| Adherence | Take medication exactly as prescribed; do not miss doses; do not stop without consulting physician |
| Rebound hypertension | Abrupt discontinuation can cause a dangerous rise in BP — always taper under medical supervision |
| Sedation warning | Drug causes drowsiness, especially at start; avoid driving or operating machinery until effects are known |
| Orthostatic hypotension | Rise slowly from sitting or lying positions; sit at bedside before standing; use grab bars |
| Alcohol | Avoid alcohol — enhances sedation and BP lowering |
| Iron supplements | Take iron at least 2 hours apart from methyldopa; report to provider if taking iron or any new supplement |
| Pregnancy | Safe during pregnancy; do not self-discontinue if pregnant — fetal risk from uncontrolled HTN is significant |
| Report symptoms | Jaundice, unusual fatigue, dark urine, fever, mood changes, persistent headache, edema — report immediately |
| Follow-up | Regular lab monitoring required; attend all scheduled appointments |
| BP self-monitoring | Instruct on home BP monitoring technique and recording |
| Salt restriction | Low-sodium diet enhances drug effectiveness and reduces fluid retention |
12.5 Special Nursing Considerations
- Elderly patients: Start at the lowest effective dose (125 mg twice daily); higher risk of sedation, falls, and cognitive impairment; reassess regularly.
- Pregnant patients: Preferred antihypertensive in all trimesters; monitor fetal growth and maternal BP closely; neonates should be observed for hypotension.
- Patients with renal impairment: Extend dosing intervals; monitor for excessive hypotension and drug accumulation.
- Post-surgical patients: Inform the surgical and anesthesia team that the patient is on methyldopa — enhanced hypotension during surgery is expected.
- If a dose is missed: Take as soon as remembered unless it is almost time for the next dose; do not double the dose.
13. CONCLUSION
Methyldopa remains a clinically relevant antihypertensive agent with a unique central mechanism of action that sets it apart from all other classes of antihypertensive drugs. Its profile as a false neurotransmitter — acting via alpha-methylnorepinephrine to reduce brainstem sympathetic outflow — offers effective blood pressure control without the reflex tachycardia characteristic of direct vasodilators.
Key clinical strengths include its unparalleled safety record in pregnancy, making it the first-line drug of choice for hypertension in pregnant women, its preservation of renal blood flow, and its proven efficacy in reducing cardiovascular events over decades of clinical use.
However, its adverse effect profile — particularly sedation, depression, positive Coombs test, hemolytic anemia, and hepatotoxicity — demands careful patient selection, thorough baseline assessment, and systematic ongoing monitoring. The risk of significant drug interactions (especially with MAOIs and iron) requires diligent nursing and pharmacist review.
The nurse's role in methyldopa therapy is multidimensional: from accurate assessment and safe administration through meticulous monitoring and comprehensive patient education. A well-informed patient who understands the rationale for treatment, the importance of adherence, and the warning signs of adverse effects is far safer and more likely to achieve therapeutic goals.
In summary, methyldopa exemplifies the principle that effective pharmacotherapy requires not just the right drug at the right dose, but informed, attentive care from every member of the healthcare team.
14. BIBLIOGRAPHY
-
Brunton LL, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 13th edition. McGraw-Hill Education; 2018. Chapters 12, 27.
-
Katzung BG, Trevor AJ, eds. Basic and Clinical Pharmacology, 15th edition. McGraw-Hill/Lange; 2021. Chapter 11: Antihypertensive Agents.
-
Kasper DL, Fauci AS, Hauser SL, et al., eds. Harrison's Principles of Internal Medicine, 21st edition. McGraw-Hill; 2022. pp. 2083, 2584 (methyldopa adverse effects and hypertension management).
-
Skidmore-Roth L. Mosby's Drug Guide for Nursing Students, 13th edition. Elsevier; 2019. Methyldopa monograph.
-
Karch AM. Focus on Nursing Pharmacology, 8th edition. Wolters Kluwer/Lippincott Williams & Wilkins; 2020.
-
World Health Organization. WHO Model List of Essential Medicines, 22nd List. WHO; 2021. Available at: www.who.int/medicines/publications/essentialmedicines.
-
American College of Obstetricians and Gynecologists (ACOG). Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin No. 222. Obstet Gynecol. 2020;135(6):e237–e260.
-
National Institute for Health and Care Excellence (NICE). Hypertension in Pregnancy: Diagnosis and Management. NICE Guideline NG133. NICE; 2019. Available at: www.nice.org.uk/guidance/ng133.
-
Micromedex Solutions (Truven Health Analytics). Methyldopa drug monograph. Accessed 2024.
-
UpToDate (Wolters Kluwer). Management of hypertension in pregnant and postpartum women. Accessed 2024.
-
British National Formulary (BNF), 86th edition. BMJ Group and Pharmaceutical Press; 2023. Methyldopa entry.
-
Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale's Pharmacology, 9th edition. Elsevier; 2019. Chapter 22: The heart, and Chapter 24: Vascular tone.
This document was prepared for educational purposes. Clinical decisions should always be guided by current national guidelines, institutional protocols, and individualized patient assessment by a qualified healthcare professional.
This is a shared conversation. Sign in to Orris to start your own chat.